|Bid||8.80 x 900|
|Ask||8.88 x 1800|
|Day's Range||8.15 - 9.11|
|52 Week Range||4.50 - 9.11|
|Beta (3Y Monthly)||2.30|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 14, 2017 - Aug 18, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.33|
News that the Senate was close to agreeing on a border deal that would avert a second government shutdown received the credit for a fast and furious rally today. The momentum slowed in the afternoon and there was no ramp up in the last 45 minutes for the first time in 15 sessions, but there were no notable pullbacks during the day.
It is still unclear if that deal will happen, but market players were not well-positioned for upside on Tuesday morning and now they are scrambling to put some cash to work. This stock has no analyst coverage and the story is still not very well-known.
In the latest trading session, Corbus Pharmaceuticals (CRBP) closed at $7.64, marking a -0.52% move from the previous day.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is aRead More...
Although the majority of U.S.-based cannabis companies and many foreign ADRs trade over-the-counter, a few marijuana companies are traded on the NASDAQ. Some investors prefer stocks that are listed on the NASDAQ to other exchanges due to their increased liquidity and tighter spreads than the OTC markets.
NEW YORK, Feb. 05, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
HENDERSON, NV / ACCESSWIRE / January 31, 2019 / With the IBB getting set to cap off its most bullish month in a while, the biotech industry could be in store for a major renaissance in 2019. Below are ...
Norwood, MA, Jan. 30, 2019 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company), a clinical stage drug development company with the industry’s.
On CNBC's "Mad Money" Monday, Jim Cramer spoke about the future of the cannabis industry. The sector traded higher on Monday on no real news, so Cramer said he can't recommend cannabis stocks as a buy. It will be possible to buy the equities at a cheaper price, the CNBC host said, adding that he still believes that legalized marijuana is one of the greatest growth stories of the era.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) (“Corbus” or the “Company), a clinical stage drug development company with the industry’s leading pipeline focused on treating inflammatory and fibrotic diseases through the endocannabinoid system pathways, today announced the pricing of an underwritten public offering of 5,390,000 shares of its common stock at a public offering price of $6.50 per share, for a total public offering size of approximately $35 million, before deducting underwriting discounts and estimated offering expenses. In addition, Corbus has granted the underwriters a 30-day option to purchase up to an additional 808,500 shares of its common stock on the same terms and conditions. Corbus intends to use the net proceeds of the proposed underwritten offering to fund its continued development of lenabasum and the compounds recently licensed from Jenrin and for general corporate purposes, which may include funding preclinical studies and clinical trials, manufacturing lenabasum and the Jenrin compounds for clinical trials and commercial launch, and acquisitions or investments in businesses, products or technologies that are complementary, and to increase its working capital and fund capital expenditures.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) (“Corbus” or the “Company”), a clinical stage drug development company with the industry’s leading pipeline focused on treating inflammatory and fibrotic diseases through the endocannabinoid system pathways, today announced that it plans to offer and sell shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Corbus. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Corbus Pharmaceuticals (CRBP) needs investors to pay close attention to the stock based on moves in the options market lately.
Collaboration in-line with Corbus vision to become the global leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemAdvances.
NEW YORK, Dec. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Company’s vision is to become the leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemLenabasum in late-stage clinical.
HENDERSON, NV / ACCESSWIRE / December 4, 2018 / The following stocks in the CBD/Biotech sectors look poised for big December's. Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), CV Sciences, ...
Curaleaf Holdings (LDVTF) is one of the leading cannabis operators in the United States. On November 16, Curaleaf Holdings announced that the company opened Tallahassee’s largest medical marijuana dispensary in the Midtown area. The above chart lists the details about Curaleaf’s new dispensary in Tallahassee.
Curaleaf Holdings (LDVTF) is one of the leading cannabis operators in the United States. Curaleaf Holdings has announced that it will release its third-quarter earnings results on November 26. Analysts expect Curaleaf Holdings to report revenue of 31.4 million Canadian dollars in the third quarter.
Corbus Pharmaceuticals Holdings (CRBP) is a clinical-stage pharmaceutical company focused on developing and commercializing products for rare, life-threatening inflammatory fibrotic diseases.
22nd Century Group (XXII) is a plant biotechnology company that’s focused on developing technologies to manage the nicotine content in tobacco plants and the cannabinoids in cannabis plants using gene editing and plant breeding technologies.
Insys Therapeutics (INSY) is among the specialty pharmaceutical companies that focus on developing cannabinoids and sprays.